Castle Biosciences Acquires AltheaDx

BioMarin Acquires Alesta Therapeutics

August 18, 2026

Biotechnology

BioMarin agreed to acquire Alesta Therapeutics for $275 million upfront, plus up to $215 million in development and regulatory milestone payments, to obtain its lead clinical-stage asset, ALE1. The acquisition closed on September 1, 2026; Alesta had spun out its non-ALE1 assets before closing, and became a wholly owned BioMarin subsidiary.

mdxhealth to Acquire Bio-Techne’s Exosome Diagnostics Business (ExoDx Prostate)

August 5, 2025

Healthcare Services

Bio-Techne Corporation has reached an agreement for mdxhealth SA to acquire its Exosome Diagnostics Inc. business, including the ExoDx Prostate (EPI) test and CLIA-certified clinical laboratory and related assets. Bio-Techne will retain access to proprietary exosome-based technology for ongoing kit development, and expects the transaction to be completed in the first quarter of fiscal 2026.

Principle Health Systems Acquires Telos PGX

December 9, 2024

Healthcare Services

Principle Health Systems has acquired Telos PGX, a CLIA/COLA pharmacogenetic testing provider focused on the long-term care market. The acquisition adds pharmacogenetic testing capabilities to Principle's mobile diagnostic services and will keep Telos founder D.J. Hart in a leadership role to scale operations and expand PGx adoption in skilled nursing facilities.

Eurobio Scientific Acquires GenDx (Genome Diagnostics B.V.)

October 4, 2022

Biotechnology

Paris-based Eurobio Scientific has acquired all outstanding shares of Dutch transplant diagnostics specialist GenDx (Genome Diagnostics B.V.), following a share purchase agreement signed on August 17. The acquisition expands Eurobio's molecular diagnostics portfolio in transplantation and secures the company legacy with proceeds funding a GenDx foundation established by the founders.

Castle Biosciences Acquires Cernostics

October 19, 2021

Healthcare Services

Castle Biosciences (Nasdaq: CSTL) has completed the acquisition of Cernostics, Inc., a Pittsburgh-based developer of the TissueCypher spatial biology and AI-driven image analysis platform, for approximately $30 million in initial consideration plus up to $50 million in performance-based milestones. The deal brings the TissueCypher Barrett's Esophagus Assay into Castle's portfolio, expanding the company's diagnostics capabilities into the gastrointestinal and oncology markets and adding an estimated ~$1 billion to Castle's U.S. TAM.

Invitae Acquires ArcherDX to Build a Precision Oncology Genetics Platform

June 22, 2020

Healthcare Services

Invitae has entered into a definitive agreement to acquire ArcherDX in a cash-and-stock transaction valued at approximately $1.4 billion, combining Invitae's diagnostic and hereditary testing capabilities with ArcherDX's somatic genomics, liquid biopsy and bioinformatics platform. The deal is intended to integrate germline and somatic testing, expand precision oncology offerings, and accelerate adoption of comprehensive cancer genetics across clinical and biopharma customers worldwide.